- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02466438
Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO) (PIP-TAZO)
Safety and Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Infants and Children
Study Overview
Detailed Description
This is a prospective, open-label Pharmacokinetics and safety study of piperacillin-tazobactam in children 2 months-6y of age.
Overall goal: To establish extended-infusion piperacillin-tazobactam dosing recommendations in infants and young children with normal renal function, for the treatment of sepsis due to resistant organisms. Dosing recommendations will be provided according to different levels of antibiotic resistance (MIC). We aim to establish the age threshold below which extended infusion does not provide additional therapeutic benefit because of immature renal function. We also aim to describe the PK of piperacillin-tazobactam standard dosing in children with acute kidney injury.
Study population #1: Normal Renal Function:
Evaluate the PK of piperacillin-tazobactam extended infusion in children 2 months-6y with normal renal function.
Hypothesis 1.1 : Population clearance of piperacillin will be 20% lower in infants 2-5 months compared with infants 6-23 months and will reach adult values at 2 years of age.
Hypothesis 1.2: Alternative dosing strategy used in this clinical trial will achieve pharmacodynamics (PD) target (50% fT > MIC) for minimum inhibitory concentration (MIC) up to 16 mg/L in 90% of infants and children 2 months-6y.
Study Population #2: Acute Kidney Injury:
Describe the PK of piperacillin-tazobactam in children with kidney injury, using the standard dosing.
Hypothesis 2.1: Population clearance of piperacillin will be 15% lower in infants with acute kidney injury but normal glomerular filtration rate (GFR). Clearance will increase as GFR decreases.
Screening:
Infants and children will be screened using a pharmacy software application available in our institution, displaying a list of all subjects meeting inclusion criteria in real time. Recruitment will take place in units where children receive piperacillin-tazobactam.
Enrollment/Baseline: Baseline/Pre-Dose Assessment:
After it has been determined that the participant satisfies all inclusion and no exclusion criteria and after the parent or legal guardian has signed the informed consent form, subjects will be assigned a study number and the following evaluations will be recorded in the clinical research form:
- Participant demographics including gender, date of birth, chronologic age, corrected age if <1 year of age and born <37 weeks of gestational age, race, birth weight if <1 year of age, and weight at time of consent.
- Active clinical diagnoses
- Concomitant medications taken in 72 hours prior to first dose of piperacillin-tazobactam or during treatment with piperacillin-tazobactam
- Laboratory and microbiologic determinations within 72 hours prior to first dose of piperacillin-tazobactam
- Microbiological results of sterile body fluids (blood, cerebrospinal fluid (CSF), urine obtained by catheterization or supra-pubic tap), within 72 hours prior to the first dose of study drug
Assessments/Procedures (Day 1 to Day 14): The following assessments will be conducted each day while the patient is on study
- Study medication administration: The date and time, amount, infusion duration and site of administration of each dose will be recorded. Day 1 will be day of first dose of study drug.
- PK samples collection: date and time of sample collection, total blood volume collected.
- Laboratory determinations on each day of PK sample collection
- Microbiological results of sterile body fluids (blood, CSF, urine obtained by catheterization or supra-pubic tap)
- Concomitant medications
- AEs
Follow-up (Day 15 to 17 or End of Therapy): The following assessments will be conducted at end of therapy:
- Laboratory determinations on the last day of study drug, or within 72h after the last study dose
- AEs up to 72h after the last study dose
Laboratory Determinations:
Any labs obtained per standard of care may be recorded while the patient is on study at the following timeline: 1) within 72 hours prior to the first dose of study medication 2) within 72h of PK sample collection 3) on Day 14 of therapy (or end of therapy, whichever comes first), or within 72h hours of last study dose will be recorded. If multiple values for a laboratory are obtained in the 72 hours prior to first dose, record the value closest to enrollment.
- Any hematology values including hemoglobin, hematocrit, white blood cell count, platelet count, and differential.
- Any serum chemistry values including blood urea nitrogen (BUN), serum creatinine, potassium, sodium, Aspartate transaminase (AST), Alanine transaminase (ALT), albumin.
- Given that renal function is the main determinant of piperacillin-tazobactam clearance, serum creatinine will be obtained prior to the first study dose, even if not done per standard of care.
Microbiological Determinations:
All results for any cultures obtained of sterile body fluids (blood, CSF, urine obtained by catheterization or supra-pubic tap) from 72 hours prior to first piperacillin-tazobactam dose through the final dose of piperacillin-tazobactam or Day 14 of therapy (whichever comes first) will be recorded in the case report form (CRF).
Special Assays or Procedures: Pharmacokinetics (PK) Samples:
During study treatment, 4 plasma PK samples (200 µL of whole blood/sample) per subject will be collected using an opportunistic approach; PK samples can be collected after any dose of study drug because PK of piperacillin is linear. PK samples will be obtained at the same time as laboratory tests collected per routine medical.
Specimen Preparation, Handling, and Shipping:
PK samples will be collected in ethylenediamine-tetra-acetic acid (EDTA) microcontainers and processed immediately or placed on ice until processing. Samples will be identified using preprinted labels with the protocol number. Plasma will be separated via centrifugation (3000g for 10 minutes at 4°C), manually aspirated and transferred to polypropylene tubes. Plasma samples will be frozen at -80°C freezer until analysis.
Once enrollment and sample collection are completed, PK samples will be shipped on dry ice to a central laboratory where piperacillin and tazobactam plasma concentrations will be measured using a validated bioanalytical assay.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- Recruiting
- St. Justine's Hospital
-
Contact:
- Julie Autmizguine, MD, MHS
- Phone Number: 5631 514 345-4931
- Email: julie.autmizguine@umontreal.ca
-
Contact:
- Mariana Dumitrascu, MD
- Phone Number: 6648 1514 345-4931
- Email: mariana.dumitrascu@recherche-ste-justine.qc.ca
-
Sub-Investigator:
- Catherine Litalien, MD, PhD
-
Sub-Investigator:
- Yves Théoret, B. Pharm., PhD
-
Sub-Investigator:
- Denis Lebel, B. Pharm.
-
Sub-Investigator:
- Céline Thibault, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study population #1: Normal renal function
Inclusion Criteria:
- Children 2 months - 6 years of age*
- Piperacillin-tazobactam indicated per standard of care
- Informed consent
Exclusion Criteria:
- Insufficient venous access to allow extended infusion
- History of anaphylaxis to β-lactams
- Supported with extracorporeal membrane oxygenation (ECMO)
- On renal replacement therapy
- Cystic fibrosis
- Acute Kidney injury
- Chronic renal insufficiency defined as defined as a glomerular filtration rate of 10-60 mL/min/1.73 m2
Study population #2: Acute Kidney injury
Inclusion Criteria:
- Children 2 months - 6 years of age
- Piperacillin-tazobactam indicated per standard of care
- Informed consent
Acute Kidney injury defined as the following:
- Doubling of serum creatinine according to upper limit of normal for age and gender or
- Doubling of baseline serum creatinine (defined as the creatinine level at admission, if the value is within normal limit for age and gender) We wil use the smaller value of these 2 definitions to diagnose acute kidney injury in a given subject.
Exclusion Criteria:
- History of anaphylaxis to β-lactams
- Supported with extracorporeal membrane oxygenation (ECMO)
- On renal replacement therapy
- Cystic fibrosis
- Chronic renal insufficiency defined as defined as a glomerular filtration rate of 10-60 mL/min/1.73 m2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Piperacillin-tazobactam
Piperacillin-tazobactam administration (fixed combination, ratio piperacillin:tazobactam = 8:1). Recruitment stratified by age group and pediatric populations to ensure good representation of those subgroups. Maximum dose: 16g/day. Treatment duration: up to 14 days depending to the treating physician. Patients with Normal Renal function:
Patients with Acute Kidney injury:
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Clearance (CL) for piperacillin and tazobactam
Time Frame: up to 14 days
|
Treatment days 1-14 followed by a safety observation period of 3 days after the last study dose.
|
up to 14 days
|
Proportion of subjects who achieve Pharmacodynamic target (at least 50% of free plasma piperacillin concentration above the MIC [50% fT > MIC])
Time Frame: up to 14 days
|
Treatment days 1-14 followed by a safety observation period of 3 days after the last study dose.
|
up to 14 days
|
Evaluation of Volume of distribution (V) for piperacillin and tazobactam
Time Frame: up to 14 days
|
Treatment days 1-14 followed by a safety observation period of 3 days after the last study dose.
|
up to 14 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects experiencing adverse events (AEs)
Time Frame: up to 17 days
|
up to 17 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julie Autmizguine, MD, MHS, St. Justine's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUSJ-4131
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Ondine Biomedical Inc.CompletedSurgical Site Infection | Nosocomial Infection | Healthcare Associated InfectionUnited States
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site InfectionUnited States
-
Croydon Health Services NHS TrustCompletedSurgical Site Infection | Wound Infection | Cesarean Section; Infection | Perineal InfectionUnited Kingdom
-
Cairo UniversityRecruitingPostoperative Infection | Cesarean Section Complications | Vaginal InfectionEgypt
-
Vastra Gotaland RegionGöteborg UniversityRecruitingProsthetic Joint Infection | Hip Prosthesis Infection | Prosthetic Infection | Knee Prosthesis InfectionSweden
-
University of ZurichRecruitingProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical SiteSwitzerland
-
Ondine Biomedical Inc.CompletedNosocomial Infection | Surgical Site Infections | Healthcare Associated InfectionsUnited States
-
Duke UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedSurgical Site Infection | Infection ControlUnited States
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... and other collaboratorsRecruitingProsthetic-joint Infection | Infection Hip | Infection; Knee, JointNetherlands
Clinical Trials on Piperacillin-tazobactam
-
Fundación Pública Andaluza para la gestión de la...Hospital Son Espases; Hospital Universitario Virgen Macarena; Hospital Son Llatzer and other collaboratorsCompletedPseudomonas Aeruginosa InfectionSpain
-
Ain Shams UniversityCompletedGram-Negative InfectionsEgypt
-
Karolinska InstitutetCompletedCholecystitis, AcuteSweden
-
European Organisation for Research and Treatment...CompletedLymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Fever, Sweats, and Hot Flashes | Bone Marrow SuppressionSwitzerland, United States, Canada, United Kingdom, Belgium, Israel, Slovakia, Finland, Germany, France, Turkey, Czech Republic, Greece
-
University Hospital, RouenNot yet recruitingPancreaticoduodenectomy | Antibiotherapy
-
Nabriva Therapeutics AGMedpace, Inc.CompletedAcute Pyelonephritis | Urinary Tract Infection Complicated | Urinary Tract Infection SymptomaticPoland, Ukraine, Belarus, Bulgaria, Romania, Greece, United States, Russian Federation, Hungary, Lithuania, Slovakia, Czechia, Latvia, Croatia, Georgia, Estonia
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedUrinary InfectionsSpain
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedGram-Positive Bacterial Infections | Klebsiella Infections | Escherichia Coli InfectionsKorea, Republic of
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDiabetes Mellitus | Diabetic Foot
-
Phillip Brian SmithCompleted